Each admission for heart failure incurs an estimated cost of $14 631, resulting in a substantial economic burden.22 The amalgamated pooled data from these trials in our study suggests an overall significant reduction in cardiovascular death or HHF, MACE outcomes, and all-cause mortality in patients treated with SGLT2-Is with every degree of comorbidity from low to high risk. The gene discussed is SLC5A2; the disease is heart failure.